Vivos Therapeutics, Inc. - 8-K Filing

Vivos Therapeutics reports Q3 2026 revenue of $6.4 million, a 24% quarter-over-quarter increase, and regained Nasdaq compliance following SOD Sciences transaction. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $VVOS

Read the full article at SEC EDGAR

More Regulatory news